Table 2.

Population data for rifampicin model development in healthy population.

No	Population	No. of Subjects	Dose	Route	Age (Years)	Weight (kg)	Female Proportion	Reference Study *
1	Healthy	2	450 mg	Intravenous infusion	25–60		0	[40]
2	Healthy	6	600 mg	Intravenous infusion	25–60		0	[40]
3	Healthy	12	300 mg	Oral	25–53	48–88	0	[41]
4	Healthy	24	600 mg	Oral	19–45	60–101.4	0	[42]
5	Healthy	18	600 mg	Oral	18–55	>50	0	[43]
6	Healthy	22	600 mg	Oral	18–55	>50	0	[44]
7	Healthy	16	600 mg	Oral	28–59	51–80	0.68	[28]
8	Healthy	18	600 mg	Oral	18–40	Mean: 68.73	0.5	[26]
9	Healthy	66	450 mg	Oral	18–55	>50	0.5	[45]
10	Healthy	61	600 mg	Oral	18–55	>50		[45]
11	Healthy	19	600 mg	Oral	19–29	49–95	0.73	[27]
12	Healthy	8	600 mg	Oral	18–50	Mean: 79.3	0.5	[46]
13	Healthy	6	10 mg/kg	Oral	60–95	44–81	0.33	[47]
14	Healthy	13	450 mg	Oral	18–45		0	[48]
15	Healthy	13	450 mg	Oral	15–59		0	[37]
16	Healthy	30	300 mg	Oral			0.5	[49]
17	Healthy	24	10 mg/kg	Oral	18–65		0.6	[15]

* All the above-mentioned clinical studies were conducted in a fasting state.